RxDoctor Payments Data

Antonio Diaz, MD

Nephrology · San Juan, PRNPI 1003016775

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.4% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.

$2,804in general payments, 2019–2025

Across 61 payments — averaging $45.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$568
  • Mallinckrodt Hospital Products Inc.$463
  • Mallinckrodt Enterprises LLC$349
  • Boston Scientific$253
  • Johnson & Johnson$195
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$172
  • plus $804 from 11 others

What the payments were for

  • Food & beverage$2,61993%
  • Education$1857%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,804 in reported general payments places this provider in the 65th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$18,659
Medicare patients
49
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate135$79,653
FarxigaDapagliflozin Propanediol74$52,312
Lanthanum Carbonate87$42,791
Sevelamer Carbonate193$34,049
Calcium Acetate203$21,086
KerendiaFinerenone26$18,574
TradjentaLinagliptin22$12,836
Sodium Polystyrene Sulfonate35$3,896
LantusInsulin Glargine,hum.Rec.Anlog29$1,934
Irbesartan52$1,259
Telmisartan33$1,247
Hydralazine Hcl60$1,050
Gabapentin92$763
Candesartan Cilexetil11$748
Metolazone19$647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$568$131,965209 claims
Boehringer IngelheimTradjenta$85$12,83622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →